News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

Atrial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

Study Status:

Active, Enrolling Participants

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The primary aim of this study is to test that apixaban is superior to aspirin for the prevention of recurrent stroke in subjects with cryptogenic ischemic stroke and atrial cardiopathy. Another ais is to test that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.


Principal Investigator
Wady Aude, MD
National Institute of Neurological Disorders and Stroke
Type of Trial
© 2023 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram